A Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects With Advanced Solid Tumors and Subsequent Dose Expansion Cohorts

NCT02266745 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

109

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumors
CRPC
mCRPC
Metastatic Castrate-resistant Prostate Cancer
PT-112
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site

Interventions

DRUG: PT-112 Injection

Sponsor

Promontory Therapeutics Inc.